Attachment Download： 
1_影像学引导下不可逆电穿孔消...肿瘤专家共识（2022版）_魏颖恬(1).pdf
Irreversible electroporation (IRE) technology has gradually gained recognition and favor in clinical practice due to its tissue-selective characteristics and high immunoreactivity. Professor Xiao Yueyong from the Department of Radiology Intervention at the Chinese PLA General Hospital and Director Wang Zhongmin from the Department of Radiology Intervention at the Shanghai Ruijin Hospital have led their teams to make extensive explorations in this field, which is at the forefront of academia. They have convened and published the first edition of the Consensus of Experts on Image-guided Irreversible Electroporation Ablation Therapy for Malignant Liver Tumors, hereafter referred to as the "Consensus."
Abstract
Irreversible electroporation (IRE) is a tumor ablation technology that is particularly suitable for solid tumors in special locations. It can avoid damaging surrounding structures such as blood vessels and bile ducts, and is commonly used for the treatment of malignant liver tumors. In recent years, Chinese experts have gained mature experience in using IRE to treat liver tumors. In order to better utilize the advantages of IRE, standardize clinical operations, and minimize related complications, domestic experts have been convened to discuss and formulate this consensus for clinical reference.
The concise explanation of nanoknife technology's technical advantages and indications in the treatment of malignant liver tumors by ablation in the "Consensus" is introduced.
Table 1 Lesion size and recommended number of electrode needles during IRE surgery.
Figure 1 The aerial view displays the relationship between the electrode needle and the tumor and blood vessels during IRE when 3-6 (A~D) electrode needles are arranged.
The "consensus" provides comprehensive professional recommendations on the prevention and treatment of complications, including arrhythmia, bleeding, thermal injury, and infection.
"The consensus" points out that the ablation effect of IRE used in the treatment of liver tumors is significantly better for lesions with a diameter ≤2 cm compared to those with a diameter >2 cm and ≤3 cm, while the ablation effect is poorer for lesions with a diameter >3 cm [11,23-25]. For liver tumors with a diameter ≤3 cm and located near important structures such as the hepatic portal, IRE can be used as the preferred treatment.
|
Wei Yingtian The First Medical Center of Chinese PLA General Hospital · Graduated in 1994, majoring in Medical Imaging at Tianjin Medical University. · Member and Secretary of the Interventional Minimally Invasive Treatment Professional Committee of China Medical Education Association · Secretary-General of the Nanoknife Tumor Ablation Branch of China Medical Education Association. · Member of the Society of Interventional Oncology (SIO). · Member of the Asian Society of Cryoablation (ASC) · Member of the Tumor Ablation Special Committee of the Chinese Medical Doctor Association Interventional Physicians Branch. · Member of the Magnetic Resonance Intervention Professional Committee of the National Minimally Invasive Treatment Industry Technology Innovation Strategic Alliance for Cancer. · Proficient in performing various procedures, such as biopsy, ablation, nanoknife, and vascular intervention, for lesions in different body parts under the guidance of imaging. · Co-authored 8 books and textbooks in both Chinese and English, translated 5 works, published over 30 academic papers, participated in 8 research projects, including 5 national natural science foundation research projects and 1 major support project of the Ministry of Science and Technology. |
|
Xiao Yueyong National Renowned Physicians--Outstanding Achievements The First Medical Center of Chinese PLA General Hospital Director of the Radiology Department · National Renowned Physicians--Outstanding Achievements · Director of the Radiology Department of the First Medical Center of the Chinese PLA General Hospital · The 21st President of the International Society of Cryosurgery. · Honorary Chairman of the Asian Society of Cryosurgery (1st-2nd President of the Asian Cryosurgery Association). · Director of the Minimally Invasive Treatment Committee of the Chinese Anti-Cancer Association. · Executive Director of the Chinese Medical Education Association. · Director of the Minimally Invasive Treatment Special Committee Intervention · Director of the Tumor Nanoknife Ablation Treatment Society. · Vice Chairman of the National Minimally Invasive Treatment Industry Technology Innovation Strategic Alliance for Cancer · Vice Chairman of the Interventional Magnetic Resonance Committee · Vice Leader of the Expert Group of the Management Specification for Tumor Ablation Treatment Technology by the National Health Commission · Deputy Director of the Interventional Physicians Branch of the Beijing Medical Association · Vice Chairman of the Interventional Medicine Branch of the Beijing Medical Association. · Editor-in-Chief of Chinese Journal of Interventional Imaging and Therapy. · Executive Editor of Chinese Journal of Medical Imaging Technology. · Executive Editor of the Chinese-English bilingual journal of Interventional Radiology. · Editorial Board of Chinese Journal of Radiology |
|
Wang Zhongmin Medical Doctor 、Postdoctoral Fellow Ruijin Hospital, Shanghai Jiaotong University School Of Medicine Radiology Interventional Department · Vice President of the Chinese Medical Association Interventional Physicians Branch. · Secretary-General of the Chinese Medical Association Radiology Interventional Committee. · Chairman of the Chinese Medical Association Radiology Interventional Gastrointestinal/Pancreatic Committee · National Health and Health Outstanding Contribution Young Experts · Shanghai Excellent Discipline Leader in the Health System · Shanghai Outstanding Specialist Physician Award · Leading Talents of Xinjiang Production and Construction Corps · Currently, I am leading three projects funded by the National Natural Science Foundation and 21 research projects at the provincial and municipal levels. · The first person has won one second prize of the Ministry of Education Science and Technology Progress Award, one second prize of the Chinese Medical Science and Technology Award, one second prize of the Huaxia Medical Science and Technology Award, and one second prize of the Shanghai Science and Technology Progress Award. · More than 90 papers and monographs have been published in domestic and international core journals, including 42 papers indexed by SCI. · Authored and co-authored seven books as the chief editor or co-editor. |
Membership
